What the FDA Relabeling of Abacavir Means for You and Your Patients
November 2008
An FDA safety alert reported studies linking potentially fatal hypersensitivity reactions with abacavir, an HIV-antiretroviral medication, to a specific HLA-B allele (HLA-B*5701). Testing patients for this allele, prior to receiving abacavir, is now recommended. Dr. O’Kane and Dr. Yao discuss what this means for you and your patients.
Presenters:
- Dennis J. O'Kane, PhD of the Division of Clinical Biochemistry & Immunology at Mayo Clinic
- Joseph D. Yao, MD of the Division of Clinical Microbiology at Mayo Clinic
Print Options
- Before viewing, print the Notes Pages.
- After viewing, obtain a Record of Viewing.
Forward to a Colleague
If you have questions, e-mail
External
link
PDF
document
Excel
document
Word
document